直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Affirms Principle of Party Presentation Allows the Parties, Not the Court, to Chart the Course of a Litigation

October 9, 2024

Authored and Edited by Emma N. Ng; Christina Ji-Hye Yang; Erik R. Puknys

In Astellas Pharma, Inc. v. Sandoz Inc., No. 23-2032 (Fed. Cir. Sept. 18, 2024), the Federal Circuit vacated the district court’s judgment and remanded the case.

Astellas’s ’780 patent relates to a sustained release formulation for the drug mirabegron. Following a bench trial, which was limited to infringement and validity under 35 U.S.C. § 112, the district court held sua sponte that the ’780 patent was invalid as directed to patent-ineligible subject matter under 35 U.S.C. § 101.

The Federal Circuit held the district court erred by disregarding the principle of party presentation and abused its discretion because patent eligibility was not raised below by Sandoz. The Federal Circuit stated that “[i]t is for the parties—not the court—to chart the course of litigation.” While Sandoz argued during oral argument that it pleaded an invalidity defense under § 101 in its answer, the Federal Circuit noted this argument was not raised on appeal and was thus forfeited.

The Federal Circuit declined to grant reassignment to a different judge on remand. The Federal Circuit was not convinced that the presiding judge could not resolve the outstanding issues impartially and fairly, particularly since the Federal Circuit clarified the “proper course for adjudication” on remand.

Tags

patentable subject matter, 35 U.S.C. § 101

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Palo Alto, CA

Washington, DC

Contacts

Emma N. Ng
Associate
Washington, DC
+1 202 408 4149
Email
Christina Ji-Hye Yang
Partner
Washington, DC
+1 202 408 4465
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP